<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425799</url>
  </required_header>
  <id_info>
    <org_study_id>CP-006-2017</org_study_id>
    <nct_id>NCT03425799</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery</brief_title>
  <official_title>Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exela Pharma Sciences, LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spinemark Corporation Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Exela Pharma Sciences, LLC.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if Tranexamic Acid can safely reduce bleeding in people
      undergoing spinal fusion surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Blood Loss</measure>
    <time_frame>From time of surgery up to 7 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of autologous or allogenic blood transfusion</measure>
    <time_frame>From time of surgery up to 7 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Measured Blood Loss</measure>
    <time_frame>From time of surgery up to 24 hours after surgery</time_frame>
    <description>Estimated as 3x cell saver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with symptomatic anemia precipitated transfusion</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events related to tranexamic acid</measure>
    <time_frame>up to 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Spinal Fusion</condition>
  <arm_group>
    <arm_group_label>Sodium Chloride 0.9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sodium Chloride 0.9% infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic Acid 10 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tranexamic Acid 10 mg/mL infused at 3 mL/kg over one hour followed by continuous infusion at 0.3 mL/kg for maximum infusion volume of 5 mL/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride 0.9% Inj</intervention_name>
    <description>Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.</description>
    <arm_group_label>Sodium Chloride 0.9%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.</description>
    <arm_group_label>Tranexamic Acid 10 mg/mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients (Male or Female) over age eighteen (&gt;18) electively undergoing
             complex spinal fusion surgery (defined as T2 to Pelvis/Sacrum and greater than 4
             Functional Spinal Units (4 discs/motion segments=5 Vertebral segments).

          -  Female subjects of childbearing potential with a negative serum (beta human chorionic
             gonadotropin [HCG]) pregnancy test at screening and urine pregnancy test at each
             admission; who are not breastfeeding; do not plan to become pregnant during the course
             of the study; and agree to use an approved method of birth control, such as condoms,
             foams, jellies, diaphragm, intrauterine device, sexual abstinence for at least 3
             months prior to study

          -  Able to provide written informed consent after risks and benefits of the study have
             been explained

          -  Able to communicate effectively with study personnel.

        Exclusion Criteria:

          -  History or presence of any clinically significant (based on the Investigator's
             judgment) cardiovascular, respiratory, metabolic, hepatic, gastrointestinal, renal,
             hematological, dermatological, neurological, or psychiatric disease or condition
             preventing the use of tranexamic acid

          -  History of renal failure or elevated creatinine above 1.4

          -  Any diagnosis of spinal tumor or intradural pathology

          -  Diagnosis of ankylosing spondylitis

          -  History or presence of acquired disturbance of color vision

          -  History of seizures

          -  History of thromboembolic event (DVT or PE) within the past year

          -  Current use of anticoagulant medications or past medical history leading to an
             abnormal coagulation profile preoperatively

          -  Subjects diagnosed with fibrinolytic disorders requiring intra-operative
             antifibrinolytic treatment; hematological disease (thromboembolic events,
             hemoglobinopathy, coagulopathy, or hemolytic disease)

          -  Significant drug sensitivity or significant allergic reaction to any drug, including
             tranexamic acid, based on the Investigator's judgment

          -  A subject who has donated or lost 450 mL or more blood volume (including
             plasmaphoresis) or had a transfusion of any product within 3 months prior to the
             initial study drug administration

          -  Pre-operative anemia (hb &lt;110 in females, Hb &lt;120 in males)

          -  Any subject that chooses to refuse blood products for ethical or religious purposes
             (Jehovah's Witness)

          -  Current participation in a drug or other investigational research study or
             participation within 30 days prior to the initial study drug administration

          -  A subject who may not be able to comply with the safety monitoring requirements of
             this clinical trial or is considered by the investigator, for any reason, to be an
             unsuitable candidate for the study.

          -  Intraoperative cardiovascular, pulmonary, orthopedic, or anesthetic complication such
             as myocardial infarction, intraoperative fracture, vasopressor support or emergent
             intubation.

          -  Female patients who are using combination hormonal contraception.

          -  Patients with history of subarachnoid hemorrhage.

          -  Patients with serum creatinine above upper limit of normal (ULN).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marcy T. Rogers, M.Ed.</last_name>
    <phone>(858) 658-0044</phone>
    <email>mrogers@spinemark.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Orthopaedic Surgery Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSF Spine Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center - Division of Spine Surgery</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spine Care Orthopedics - NYU Lagone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington - Department of Orthopaedics and Sports Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brian Hsu</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2067</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Calvary Hospital</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

